Endocrinology & Diabetes ResearchISSN: 2470-7570

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Editorial, J Metabonomics Metabolites Vol: 1 Issue: 2

Metabolism and Metabonomics in Cancer Risk Assessment, Diagnosis, Prognosis and Treatment

M. Čuperlović-Culf1,2,3,4*
1National Research Council, Moncton, Canada
2Department of Chemistry and Biochemistry, Université de Moncton, Moncton, Canada
3Department of Chemistry and Biochemistry, Mount Allison University, Sackville, Canada
4Atlantic Cancer Research Institute, Moncton, Canada
Corresponding author : M. Cuperlovic-Culf, PhD
National Research Council Canada, 100 des Aboiteaux street, Moncton, New Brunswick, E1A 7R1, Canada
Tel: 506-861-0952; Fax: 506-851-3630
E-mail: miroslava.cuperlovic-culf@nrc-cnrc.gc.ca
Received: November 14, 2012 Accepted: November 16, 2012 Published: November 19, 2012
Citation: Cuperlovic-Culf M (2012) Metabolism and Metabonomics in Cancer Risk Assessment, Diagnosis, Prognosis and Treatment. J Metabonomics Metabolites 1:2. doi:10.4172/2325-9736.1000e108

Abstract

Metabolism and Metabonomics in Cancer Risk Assessment, Diagnosis, Prognosis and Treatment

Cancer is a genetic disease – changes to the cell’s DNA lead to malignant transformation and known hallmarks of cancer. Genetic or epigenetic mutations leading to altered expression levels and activation of oncogenes and oncosuppressor genes reprogram metabolism as well and this further promotes tumor progression. There are now many experimental and clinical proofs of the significance of cancer metabolic phenotype in cancer’s development, growth and metastasis.

international publisher, scitechnol, subscription journals, subscription, international, publisher, science

Track Your Manuscript

Awards Nomination

Media Partners

open access